文献速递新生儿儿童呼吸

早期吸入一氧化氮与肺发育不良早产儿生存的关联

Association of Early Inhaled Nitric Oxide With the Survival of Preterm Neonates With Pulmonary Hypoplasia.
PubMed 文献 · JAMA Pediatr · 2018-07-02

该队列研究纳入92 635名极早产儿,其中767名(0.8%)诊断为肺发育不良,185名(0.2%)在生后第一周接受吸入一氧化氮。经1:1倾向评分匹配151对后,吸入一氧化氮与院内死亡无显著关联(HR 0.79;95%CI 0.57-1.11)。

要点

  • 极早产儿肺发育不良病死率高,早期吸入一氧化氮未改善生存。
  • 匹配队列中吸入一氧化氮与死亡风险无显著关联(HR 0.79;95%CI 0.57-1.11)。
  • 伴或不伴PPHN亚组均无显著关联,但可能存在 ascertainment bias。

核心结论

  • 对于胎龄22-29周、出生体重≥400g且诊断为肺发育不良的极早产儿,生后第一周开始吸入一氧化氮治疗与院内生存改善无显著关联。

研究设计与样本

  • 这项队列研究使用Pediatrix Medical Group临床数据仓库中来自美国35个州和波多黎各350余个NICU的数据。
  • 暴露定义为生后第0-7天内某天开始吸入一氧化氮,并采用1:1倾向评分匹配减少两组间可测协变量失衡。

主要发现

  • 研究样本共92 635名新生儿,其中767名(0.8%)符合全部纳入标准且诊断为肺发育不良,185名(0.2%)暴露于吸入一氧化氮。
  • 在151对匹配的暴露与未暴露新生儿中,吸入一氧化氮与死亡无显著关联(HR 0.79;95%CI 0.57-1.11)。
  • 合并PPHN的肺发育不良亚组中HR为0.67(95%CI 0.45-1.01),不合并PPHN亚组中HR为1.11(95%CI 0.61-2.02),均无显著关联,但可能受 ascertainment bias 影响。

关键数值与推荐

  • 主要结局为死亡(定义为转院前或出院回家前死亡)。
  • 次要结局包括任何期别坏死性小肠结肠炎、需治疗的早产儿视网膜病变、慢性肺疾病和脑室周围白质软化。
  • 匹配分析采用1:1倾向评分匹配,暴露组与未暴露组各151名。

临床怎么用

  • 对于极早产儿肺发育不良,早期吸入一氧化氮不应被视为改善生存的常规治疗选择。
  • 临床决策需权衡个体情况,并考虑该研究未显示生存获益的结果。

局限性

  • 吸入一氧化氮非随机分配,尽管采用倾向评分匹配,仍可能存在未测量混杂。
  • 亚组分析结果可能受 ascertainment bias 影响。
  • 结论需临床试验进一步澄清。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pulmonary hypoplasia affects a very small percentage of preterm neonates, but its presence is associated with high rates of mortality. OBJECTIVE: To determine whether treatment with inhaled nitric oxide during the first week of life was associated with improved in-hospital survival in a cohort of extremely preterm neonates with pulmonary hypoplasia. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the Pediatrix Medical Group's Clinical Data Warehouse, a data set containing information from more than 350 neonatal intensive care units in 35 US states and Puerto Rico. Since inhaled nitric oxide was not randomly prescribed, we used 1-to-1 propensity score matching to reduce the imbalance of measured covariates between the 2 treatment groups. The initial, unmatched cohort included singleton neonates who were born between 22 and 29 weeks' gestation, had a birth weight of 400 g or more, were diagnosed with pulmonary hypoplasia as a cause of their respiratory distress, remained free of major anomalies, and were discharged between January 1, 2000, and December 31, 2014. We defined exposure as the initiation of inhaled nitric oxide on day t in days 0 to 7 of the life of a neonate. Each exposed neonate was matched 1-to-1 to a neonate who had not initiated inhaled nitric oxide on a given day. MAIN OUTCOMES AND MEASURES: The primary outcome was mortality defined as death prior to transfer or discharge home. Secondary outcomes were any-stage necrotizing enterocolitis, retinopathy of prematurity requiring treatment, chronic lung disease, and periventricular leukomalacia. RESULTS: Among 92 635 neonates in our study sample, we identified 767 (0.8%) with pulmonary hypoplasia who met all study inclusion criteria, of whom 185 (0.2%) were exposed to inhaled nitric oxide. Among 151 matched pairs of exposed and unexposed neonates, we did not identify a significant association between inhaled nitric oxide use and mortality (hazard ratio [HR], 0.79; 95% CI, 0.57-1.11). Subgroup analyses of neonates with and without persistent pulmonary hypertension (PPHN) likewise revealed no significant association between inhaled nitric oxide use and mortality (pulmonary hypoplasia with PPHN: HR, 0.67; 95% CI, 0.45-1.01; pulmonary hypoplasia without PPHN: HR, 1.11; 95% CI, 0.61-2.02), but these findings may have been influenced by ascertainment bias. CONCLUSIONS AND RELEVANCE: Early treatment with inhaled nitric oxide is not associated with improved survival among extremely preterm neonates with pulmonary hypoplasia. Clinical trials are warranted to clarify the matter.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Ellsworth KR, Ellsworth MA, Weaver AL, et al. Association of Early Inhaled Nitric Oxide With the Survival of Preterm Neonates With Pulmonary Hypoplasia. JAMA Pediatr. 2018. PMID: 29800952. doi:10.1001/jamapediatrics.2018.0761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。